HC Wainwright Reiterates “Buy” Rating for BriaCell Therapeutics (NASDAQ:BCTX)

HC Wainwright reaffirmed their buy rating on shares of BriaCell Therapeutics (NASDAQ:BCTX) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $15.00 target price on the stock. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.20) EPS and FY2029 earnings at $0.24 EPS.

BriaCell Therapeutics Stock Down 2.9 %

NASDAQ:BCTX opened at $1.01 on Tuesday. The firm has a market cap of $36.54 million, a price-to-earnings ratio of -0.86 and a beta of 1.46. BriaCell Therapeutics has a 12 month low of $0.46 and a 12 month high of $5.97. The company’s 50 day moving average is $0.84 and its 200-day moving average is $0.91.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.45. Research analysts predict that BriaCell Therapeutics will post -0.58 EPS for the current fiscal year.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.